News

Shilpa Medicare Limited submitted a certificate dated October 2, 2026, to the Bombay Stock Exchange and the National Stock Exchange of India, in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, with Kfin Technologies Limited acting as the Registrar and Share Transfer Agent.

Shilpa Medicare Limited will close its trading window for designated persons and their immediate relatives, as well as connected persons, from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026, in accordance with its code of conduct for prohibition of insider trading.

Shilpa Medicare Limited announced that its board of directors recommended a dividend of Re. 0.60 per equity share for the financial year ended March 31, 2026, and fixed September 4, 2026, as the record date. The company will deduct tax at source (TDS) on the dividend paid to shareholders, requiring them to update their Permanent Account Number (PAN) and other details in their demat accounts to ensure accurate tax application.

Shilpa Medicare announced that the 39th Annual General Meeting(AGM) of the company will be held on 11 September 2026.

Shilpa Medicare announced that Dr. Uday N. Harle has been appointed as the Chief Executive Officer (CEO) - Shilpa Biologicals, a wholly owned subsidiary of Shilpa Medicare (Senior Managerial Personnel) of the Company with effect from 03 August 2026.